Holen Sie sich die Stockscreener-App
14.04
2.64%
-0.38
Schlusskurs vom Vortag:
$14.42
Offen:
$14.11
24-Stunden-Volumen:
1.04M
Relative Volume:
0.27
Marktkapitalisierung:
$1.50B
Einnahmen:
$64.52M
Nettoeinkommen (Verlust:
$-95.55M
KGV:
-13.81
EPS:
-1.0169
Netto-Cashflow:
$-84.65M
1W Leistung:
-0.85%
1M Leistung:
-6.59%
6M Leistung:
+71.01%
1J Leistung:
+201.29%
1-Tages-Spanne:
$13.92
$14.33
1-Wochen-Bereich:
$13.87
$14.81
52-Wochen-Spanne:
$4.44
$16.39
Personalis Inc Stock (PSNL) Company Profile
Firmenname
Personalis Inc
Sektor
Branche
Telefon
650-752-1300
Adresse
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, NTRA, IDXX, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
14.04 | 1.52B | 64.52M | -95.55M | -84.65M | -1.0169 |
TMO
Thermo Fisher Scientific Inc
|
588.29 | 222.96B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.45 | 144.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
309.93 | 45.54B | 2.50B | -226.32M | 71.51M | -1.6412 |
IDXX
Idexx Laboratories Inc
|
550.96 | 44.95B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
148.53 | 41.87B | 7.23B | 1.41B | 1.09B | 4.979 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-03-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-06 | Hochstufung | Needham | Hold → Buy |
| 2022-01-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Herabstufung | Needham | Buy → Hold |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-20 | Bestätigt | Needham | Buy |
| 2021-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-12 | Bestätigt | Needham | Buy |
| 2020-11-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-07-15 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Personalis Inc Aktie (PSNL) Neueste Nachrichten
What Personalis (PSNL)'s Rising Revenue But Deepening Losses Means For Shareholders - simplywall.st
Ameriprise Financial (PSNL) discloses 5.8% ownership stake in Personalis common stock - Stock Titan
Deep Track Capital (PSNL) reports 4,000,000 Personalis shares, now under 5% ownership - Stock Titan
Sei Investments Co. Buys 83,040 Shares of Personalis, Inc. $PSNL - MarketBeat
Personalis, Inc. (PSNL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Personalis Inc (PSNL) Shares Fall 3.2% -- What GF Score of 53 Te - GuruFocus
Personalis, Inc. $PSNL Stock Holdings Lifted by Dimensional Fund Advisors LP - MarketBeat
Personalis (PSNL) Is Up 6.1% After Q2 Revenue Rises But Losses DeepenWhat's Changed - webull.com
Personalis Inc (PSNL) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Tempus AI Stock Drops As $1.5B Personalis Deal Ups The MRD Stakes - StocksToTrade
Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Personalis Inc (PSNL) Stock News Today - tradingkey.com
Cancer Detection Test Receives Regulatory Marking for Use in Great Britain - Clinical Lab Products
Growth Potential For Personalis, Inc. (PSNL): A Look At Its 30% Revenue Surge - DirectorsTalk Interviews
Lake Street Maintains Personalis(PSNL.US) With Hold Rating, Maintains Target Price $16.25 - Moomoo
Personalis Reports Second Quarter 2026 Results and Recent Highlights - biospace.com
Is Personalis Inc (PSNL) Significantly Overvalued Even After Q2 Revenue of $22.4 Million? GF Score: 59/100 - GuruFocus
Personalis : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Personalis (NASDAQ:PSNL) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Personalis, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Personalis, Inc. Q2 2026: Revenue $22.36M, EPS $(0.30) — 10-Q Summary - TradingView
Earnings Flash (PSNL) Personalis, Inc. Reports Q2 Revenue $22.4M, vs. FactSet Est of $16.7M - marketscreener.com
Personalis Q2 revenue rises 30% to $22.4 million - quiverquant.com
Personalis Q2 revenue rises 30%, beats estimates on expanded Medicare coverage - TradingView
Personalis (NASDAQ: PSNL) posts larger loss and strikes Tempus cash-stock merger - stocktitan.net
Personalis: Q2 Earnings Snapshot - marketscreener.com
Personalis (NASDAQ: PSNL) Q2 revenue jumps 30% as clinical tests surge - Stock Titan
Personalis Reports Second Quarter Results and Recent Highlights - marketscreener.com
PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AI - marketscreener.com
Swiss National Bank Invests $671,000 in Personalis, Inc. $PSNL - MarketBeat
How Investors May Respond To Tempus AI (TEM) Q2 Profit Return, Outlook Hike, Personalis Deal - Yahoo Finance
Tempus AI buys Personalis for $1.7B as digital health M&A su - MarketScale
TEM: Q2 revenue up 22% YoY, with major deals, FDA wins, and Personalis acquisition fueling growth - TradingView
Tempus AI buys Personalis to strengthen AI-driven cancer monitoring platform - Mugglehead Investment Magazine
PSNL|Personalis Inc|Price:11.989|Chg%:+0.209 - TradingKey
Personalis Inc (PSNL) Valuation: PE, PB & Fair Value Analysis - TradingKey
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - globenewswire.com
Tempus AI Stock (TEM) Opinions on Personalis Acquisition and Analyst Upgrades - Quiver Quantitative
Tempus AI to Acquire Personalis in $1.5 Billion Deal, Deepening Its Foothold in Cancer Monitoring - Oncodaily
Personalis Inc (PSNL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tempus to buy cancer test maker Personalis for $1.5 billion - AOL.ca
Personalis Inc (PSNL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Personalis Inc (PSNL) Income Statement - TradingKey
Tempus AI buys Personalis for $1.5B; UCSF Health, Kleiner Perkins and Doerr Capital launch health AI accelerator; Candid Health raises $120M - VatorNews
Tempus to acquire Personalis in $1.5 billion deal to expand MRD capabilities - DOTmed
Kalpesh Patel: The Fifth MRD Buyout in Less Than a Year - Oncodaily
Why Is PSNL Stock Up 5% After-Hours? - Stocktwits
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
Tempus makes $1.5B bet to corner cancer-test market - thestreet.com
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring - Sahm
Finanzdaten der Personalis Inc-Aktie (PSNL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):